Paul Szabolcs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul Szabolcs has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Xiaohua Chen
Division of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
6 shared publications - Luciana Cavalheiro Marti
Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein - Department of Experimental Research, Brazil
4 shared publications - Maria L. Escolar
Department of Pediatrics University of Pittsburgh Pittsburgh Pennsylvania USA
4 shared publications Jeyaraj Antony
Department of Pediatrics, Duke University Medical Center, Durham, NC; Pediatric Blood and Marrow Transplantation and Cellular Therapy, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa
3 shared publicationsMark Vander Lugt
Division of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
3 shared publicationsCraig C. Davis
Department of Pediatrics, Pediatric Blood and Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27705, USA
2 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Durable hematopoiesis and tolerance after vertebral bone marrow transplant from a deceased lung transplant donor
We hypothesized that performing bone marrow transplant (BMT) using marrow extracted from the vertebral bodies (VB) of an unrelated deceased lung transplant (LTX) donor would be able to establish persistent hematopoiesis, generate immunity, and tolerance. A teenager with severe combined immunodeficiency with lung failure due to recurrent pneumonias underwent LTX in 2016 from a 1/8 HLA allele-matched unrelated donor, followed by BMT 4 months later using T-cell/B-cell-depleted, cryopreserved VB marrow. Rapid engraftment was followed by accelerating immune competence at 6 months, with independence from immunosuppression by 16 months. Donor T-cell (>95%) and myeloid chimerism (7-10%) have persisted for over nine years. At two years post-BMT, circulating T cells were hyporesponsive to host dendritic cells in vitro. T-cell receptor clonotyping revealed the disappearance of host-reactive clones, and T-cell RNA-sequencing exhibited downmodulated signaling pathways for cytotoxicity/rejection, paired with upregulated immunomodulatory pathways, suggesting active suppression. In parallel, host monocytes upregulated certain signaling pathways, indicating active interactions between post-thymic donor T cells and host monocytes. In summary, durable hematopoietic engraftment, immunity, and tolerance were demonstrable for the first time in a recipient of BMT obtained from VB graft.
- 3 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Open AccessDurable hematopoiesis and tolerance after vertebral bone marrow transplant from a deceased lung transplant donor
We hypothesized that performing bone marrow transplant (BMT) using marrow extracted from the vertebral bodies (VB) of an unrelated deceased lung transplant (LTX) donor would be able to establish persistent hematopoiesis, generate immunity, and tolerance. A teenager with severe combined immunodeficiency with lung failure due to recurrent pneumonias underwent LTX in 2016 from a 1/8 HLA allele-matched unrelated donor, followed by BMT 4 months later using T-cell/B-cell-depleted, cryopreserved VB marrow. Rapid engraftment was followed by accelerating immune competence at 6 months, with independence from immunosuppression by 16 months. Donor T-cell (>95%) and myeloid chimerism (7-10%) have persisted for over nine years. At two years post-BMT, circulating T cells were hyporesponsive to host dendritic cells in vitro. T-cell receptor clonotyping revealed the disappearance of host-reactive clones, and T-cell RNA-sequencing exhibited downmodulated signaling pathways for cytotoxicity/rejection, paired with upregulated immunomodulatory pathways, suggesting active suppression. In parallel, host monocytes upregulated certain signaling pathways, indicating active interactions between post-thymic donor T cells and host monocytes. In summary, durable hematopoietic engraftment, immunity, and tolerance were demonstrable for the first time in a recipient of BMT obtained from VB graft.
- Open Access
- 10 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3502-3517
Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults
Allogeneic hematopoietic cell transplantation (allo-HCT) can provide curative treatment for hematologic malignancies but is associated with prolonged lymphopenia that may contribute to an increased risk of infection and relapse, resulting in decreased survival. We hypothesized that patients with rapid and robust CD4 T- and B-cell recovery have improved survival and decreased treatment-related mortality (TRM). A total of 2089 patients were included who underwent first allo-HCT for acute myeloid leukemia/acute lymphoblastic leukemia/myelodysplastic syndrome from 2008 to 2019 reported to the Center for International Blood and Marrow Transplant Research with available CD4 counts at days 100 and 180. Patients (median age, 51 years [range, 2-75]) were categorized into 4 groups based on graft-versus-host disease (GVHD) prophylaxis: ex vivo T-cell depletion (TCD/CD34), posttransplant cyclophosphamide, calcineurin inhibitor alone (CNI), or CNI with antithymocyte globulin. Based upon survival, we could identify optimal cutoff points for CD4+ T cells in pediatric (age of 20 years) patients: 104 × 106/L and 115 × 106/L at days 100 and 180, respectively. In adults, day-100 CD4 count was associated with overall survival (OS), progression-free survival (PFS), and TRM but not relapse, incidence of infections, or chronic GVHD. Similarly, CD4 counts above the cutoff point at day 180 in adults were associated with improved OS, PFS, and TRM but no other outcomes. No clinical associations for CD4 counts were identifiable in pediatric patients. These findings underscore the importance of tailoring transplant strategies for adults to optimize immune recovery and improve patient outcomes.
- 10 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3502-3517
Open AccessDelayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults
Allogeneic hematopoietic cell transplantation (allo-HCT) can provide curative treatment for hematologic malignancies but is associated with prolonged lymphopenia that may contribute to an increased risk of infection and relapse, resulting in decreased survival. We hypothesized that patients with rapid and robust CD4 T- and B-cell recovery have improved survival and decreased treatment-related mortality (TRM). A total of 2089 patients were included who underwent first allo-HCT for acute myeloid leukemia/acute lymphoblastic leukemia/myelodysplastic syndrome from 2008 to 2019 reported to the Center for International Blood and Marrow Transplant Research with available CD4 counts at days 100 and 180. Patients (median age, 51 years [range, 2-75]) were categorized into 4 groups based on graft-versus-host disease (GVHD) prophylaxis: ex vivo T-cell depletion (TCD/CD34), posttransplant cyclophosphamide, calcineurin inhibitor alone (CNI), or CNI with antithymocyte globulin. Based upon survival, we could identify optimal cutoff points for CD4+ T cells in pediatric (age of 20 years) patients: 104 × 106/L and 115 × 106/L at days 100 and 180, respectively. In adults, day-100 CD4 count was associated with overall survival (OS), progression-free survival (PFS), and TRM but not relapse, incidence of infections, or chronic GVHD. Similarly, CD4 counts above the cutoff point at day 180 in adults were associated with improved OS, PFS, and TRM but no other outcomes. No clinical associations for CD4 counts were identifiable in pediatric patients. These findings underscore the importance of tailoring transplant strategies for adults to optimize immune recovery and improve patient outcomes.
- 3 December 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (3) , 406-411
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT
- 3 December 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (3) , 406-411
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT
- 8 July 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (10) , 1091-1100
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases
- 8 July 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (10) , 1091-1100
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 39
First-in-human phase 1/2 trial of intravenous FBX-101 following hematopoietic stem cell transplantation increases GALC activity, supports brain development, and improves motor function in patients with infantile Krabbe disease: RESKUE clinical trial
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 39
First-in-human phase 1/2 trial of intravenous FBX-101 following hematopoietic stem cell transplantation increases GALC activity, supports brain development, and improves motor function in patients with infantile Krabbe disease: RESKUE clinical trial
- Open Access
- 6 September 2022
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 11 (Supplement) , S11
Abstract 9 Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel Leads to Robust Recovery and Diversity of T Cells
Omidubicel is a cell therapy used for allogeneic hematopoietic stem cell transplant. A phase III randomized study (NCT02730299) comparing omidubicel to umbilical cord blood (UCB) demonstrated faster hematopoietic recovery, lower rates of infection, shorter hospitalization time (Horwitz et al.Blood. 2021;138[16]:1429-1440) and robust immune reconstitution (Szaboles et al. Trans Cell Ther. 2022;28[suppl]:S5). We now characterize T-cell development reflected by T-cell receptor excision circles (TREC) and T-cell receptor (TCR) diversity in omidubicel and UCB-transplanted patients (pts). Genomic DNA was extracted from peripheral blood mononuclear cells. TREC was quantified by real-time quantitative PCR. TREC copies (T) were standardized to β actin transcripts (B), and T/B ratio was normalized per µg of DNA. TCR diversity was measured using a total of 76 T-cell receptor β locus (TRB) genes. Human T-cell receptor β repertoire was quantified using AmpliSeq for Illumina Immune Repertoire Plus SR assay. TCRβ metrics quantified the number of clones, Shannon’s entropy, clonality, evenness, convergency, and Gini indexes. A total of 37 pts from 15 sites were included, 17 transplanted with omidubicel and 20 with UCB. Median CD3+ cell dose was lower for pts transplanted with omidubicel (1.8 × 106 cells/kg; range: 1.2-7.6) than with UCB (6.0 × 106 cells/kg, range: 1.7-10.2). Patients transplanted with omidubicel and UCB had similar TREC and recent thymic emigrants (RTE) counts in peripheral blood at days 100 and 180. At day 365, RTEs were higher in omidubicel (113 ± 85 cells/µL) than UCB (41 ± 15 cells/µL, P = .047). Median T/B ratio was 223 for omidubicel and 124 for UCB. There was no significant difference in TCR repertoire diversity between the omidubicel and UCB groups. Pts transplanted with omidubicel had robust and diverse T-cell reconstitution. Higher numbers of de-novo thymus educated T-cells in peripheral blood at 1 year suggest faster thymopoiesis in patients transplanted with omidubicel than with UCB. These data are further evidence for the robust immune reconstitution in patients treated with omidubicel and provide mechanistic rationale for the lower infection rates and improved outcomes in these patients.
- 6 September 2022
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 11 (Supplement) , S11
Open AccessAbstract 9 Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel Leads to Robust Recovery and Diversity of T Cells
Omidubicel is a cell therapy used for allogeneic hematopoietic stem cell transplant. A phase III randomized study (NCT02730299) comparing omidubicel to umbilical cord blood (UCB) demonstrated faster hematopoietic recovery, lower rates of infection, shorter hospitalization time (Horwitz et al.Blood. 2021;138[16]:1429-1440) and robust immune reconstitution (Szaboles et al. Trans Cell Ther. 2022;28[suppl]:S5). We now characterize T-cell development reflected by T-cell receptor excision circles (TREC) and T-cell receptor (TCR) diversity in omidubicel and UCB-transplanted patients (pts). Genomic DNA was extracted from peripheral blood mononuclear cells. TREC was quantified by real-time quantitative PCR. TREC copies (T) were standardized to β actin transcripts (B), and T/B ratio was normalized per µg of DNA. TCR diversity was measured using a total of 76 T-cell receptor β locus (TRB) genes. Human T-cell receptor β repertoire was quantified using AmpliSeq for Illumina Immune Repertoire Plus SR assay. TCRβ metrics quantified the number of clones, Shannon’s entropy, clonality, evenness, convergency, and Gini indexes. A total of 37 pts from 15 sites were included, 17 transplanted with omidubicel and 20 with UCB. Median CD3+ cell dose was lower for pts transplanted with omidubicel (1.8 × 106 cells/kg; range: 1.2-7.6) than with UCB (6.0 × 106 cells/kg, range: 1.7-10.2). Patients transplanted with omidubicel and UCB had similar TREC and recent thymic emigrants (RTE) counts in peripheral blood at days 100 and 180. At day 365, RTEs were higher in omidubicel (113 ± 85 cells/µL) than UCB (41 ± 15 cells/µL, P = .047). Median T/B ratio was 223 for omidubicel and 124 for UCB. There was no significant difference in TCR repertoire diversity between the omidubicel and UCB groups. Pts transplanted with omidubicel had robust and diverse T-cell reconstitution. Higher numbers of de-novo thymus educated T-cells in peripheral blood at 1 year suggest faster thymopoiesis in patients transplanted with omidubicel than with UCB. These data are further evidence for the robust immune reconstitution in patients treated with omidubicel and provide mechanistic rationale for the lower infection rates and improved outcomes in these patients.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 333
Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel Is Associated with Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood Transplantation
Introduction Omidubicel is an advanced cell therapy for allogeneic hematopoietic stem cell transplantation (HSCT), derived from appropriately HLA-matched umbilical cord blood (UCB) and comprised of ex-vivo expanded CD133+ cells and a non-cultured lymphocyte-containing fraction. Recent results of a global phase III trial of omidubicel vs standard UCB showed more rapid hematopoietic recovery, reduced rates of infection, and shorter hospitalizations in patients (pts) randomized to omidubicel (Horwitz et al, Blood, 2021). We now report results of correlative immune reconstitution (IR) studies in this trial (NCT02730299). Methods A total of 125 pts aged 13-65 with hematologic malignancies were randomized to allogeneic transplantation with omidubicel or standard UCB following myeloablative conditioning; 108 pts were transplanted per protocol. An optional IR sub-study was conducted and blood was collected at intervals from Day 7 through one year post-transplant. Cryopreserved samples were analyzed in a central laboratory (Covance) using 16-color and 14-color panels and flow cytometric assays to explore T cell, NK cell, B cell, monocyte, and dendritic cell (DC) subsets. Means, medians, ranges, and standard errors were used to summarize cell counts, and one-tailed t-tests were used to compare counts in the two treatment arms. Results A total of 37 pts from 15 sites consented to the IR sub-study, representing 34% of the per protocol population; 17 pts were transplanted with omidubicel and 20 pts with control (15 [75%] of control with double UCB). Median age was 30 (range: 13-62) years for omidubicel pts and 43 (range: 19-55) years for controls in the sub-study. Median CD3+ content of omidubicel prior to cryopreservation was lower (180 x 10^6; range: 71-580 cells) than that of controls post-thaw (516 x 10^6, range: 183-990 cells). Omidubicel pts achieved neutrophil engraftment at a median of 10 (range: 6-28) days post-transplant compared to a median of 18.5 (range: 14-40) days in controls. Omidubicel pts had fewer BMT-CTN Grade 3 viral infections in the first-year post-transplant than controls (6% vs. 25%, respectively). At Day 7 post-transplant, CD4+ T cell counts were significantly higher in omidubicel pts (37x10^3 cells/ml) than in controls (17x10^3 cells/ml, p=0.011). B cells (12x10^3 vs 1x10^3 cells/ml, p=0.013) and NK cells (6x10^3 vs 3 x10^3 cells/ml, p=0.016), as well as monocyte and DC subsets, were also significantly higher in omidubicel pts (Table). Day 14 results similarly demonstrated higher counts of circulating immune cell subsets in omidubicel pts than in controls (Table). Higher B cell counts were observed in omidubicel pts than in controls at 6 months ([863±463] x10^3 vs. [543±221] x10^3 cells/ml, p=0.03) and one year ([1492±370] x10^3 vs [763±150] x10^3, p=0.02) following transplant (Figure). Conclusions Circulating immune cell subsets were consistently higher in omidubicel pts than controls as early as one week after transplant, and higher B cell counts persisted through one year. These findings correlated with the clinical observation of fewer severe bacterial, fungal, and viral infections in pts treated with omidubicel compared to standard UCB. These results demonstrate that rapid hematopoietic recovery in pts transplanted with omidubicel is accompanied by the early and robust appearance of a broad array of lymphocyte, monocyte, DC, and NK cell subsets, despite substantially fewer numbers of these cells infused, suggesting a facilitator effect of omidubicel on their in vivo expansion.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 333
Open AccessHematopoietic Stem Cell Transplantation (HSCT) with Omidubicel Is Associated with Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood Transplantation
Introduction Omidubicel is an advanced cell therapy for allogeneic hematopoietic stem cell transplantation (HSCT), derived from appropriately HLA-matched umbilical cord blood (UCB) and comprised of ex-vivo expanded CD133+ cells and a non-cultured lymphocyte-containing fraction. Recent results of a global phase III trial of omidubicel vs standard UCB showed more rapid hematopoietic recovery, reduced rates of infection, and shorter hospitalizations in patients (pts) randomized to omidubicel (Horwitz et al, Blood, 2021). We now report results of correlative immune reconstitution (IR) studies in this trial (NCT02730299). Methods A total of 125 pts aged 13-65 with hematologic malignancies were randomized to allogeneic transplantation with omidubicel or standard UCB following myeloablative conditioning; 108 pts were transplanted per protocol. An optional IR sub-study was conducted and blood was collected at intervals from Day 7 through one year post-transplant. Cryopreserved samples were analyzed in a central laboratory (Covance) using 16-color and 14-color panels and flow cytometric assays to explore T cell, NK cell, B cell, monocyte, and dendritic cell (DC) subsets. Means, medians, ranges, and standard errors were used to summarize cell counts, and one-tailed t-tests were used to compare counts in the two treatment arms. Results A total of 37 pts from 15 sites consented to the IR sub-study, representing 34% of the per protocol population; 17 pts were transplanted with omidubicel and 20 pts with control (15 [75%] of control with double UCB). Median age was 30 (range: 13-62) years for omidubicel pts and 43 (range: 19-55) years for controls in the sub-study. Median CD3+ content of omidubicel prior to cryopreservation was lower (180 x 10^6; range: 71-580 cells) than that of controls post-thaw (516 x 10^6, range: 183-990 cells). Omidubicel pts achieved neutrophil engraftment at a median of 10 (range: 6-28) days post-transplant compared to a median of 18.5 (range: 14-40) days in controls. Omidubicel pts had fewer BMT-CTN Grade 3 viral infections in the first-year post-transplant than controls (6% vs. 25%, respectively). At Day 7 post-transplant, CD4+ T cell counts were significantly higher in omidubicel pts (37x10^3 cells/ml) than in controls (17x10^3 cells/ml, p=0.011). B cells (12x10^3 vs 1x10^3 cells/ml, p=0.013) and NK cells (6x10^3 vs 3 x10^3 cells/ml, p=0.016), as well as monocyte and DC subsets, were also significantly higher in omidubicel pts (Table). Day 14 results similarly demonstrated higher counts of circulating immune cell subsets in omidubicel pts than in controls (Table). Higher B cell counts were observed in omidubicel pts than in controls at 6 months ([863±463] x10^3 vs. [543±221] x10^3 cells/ml, p=0.03) and one year ([1492±370] x10^3 vs [763±150] x10^3, p=0.02) following transplant (Figure). Conclusions Circulating immune cell subsets were consistently higher in omidubicel pts than controls as early as one week after transplant, and higher B cell counts persisted through one year. These findings correlated with the clinical observation of fewer severe bacterial, fungal, and viral infections in pts treated with omidubicel compared to standard UCB. These results demonstrate that rapid hematopoietic recovery in pts transplanted with omidubicel is accompanied by the early and robust appearance of a broad array of lymphocyte, monocyte, DC, and NK cell subsets, despite substantially fewer numbers of these cells infused, suggesting a facilitator effect of omidubicel on their in vivo expansion.
- Open Access
- 28 August 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (12) , 3823-3824
Hemophagocytic syndrome with graft-versus-host disease after liver transplantation: The bone marrow as a not so quiet battlefield?
- 28 August 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (12) , 3823-3824
Open AccessHemophagocytic syndrome with graft-versus-host disease after liver transplantation: The bone marrow as a not so quiet battlefield?
- Open Access
- 1 April 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (13) , 1719-1730
Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease
Krabbe disease is a rare neurodegenerative disorder caused by a deficiency in galactocerebrosidase. The only effective treatment is hematopoietic stem cell transplantation (HSCT). Approximately 85% of Krabbe disease cases are the infantile subtypes, among which ∼20% are late infantile. Prior studies have demonstrated that HSCT is effective for early-infantile patients (0-6 months of age) who undergo transplantation while asymptomatic, compared with those receiving transplants while symptomatic. However, no studies evaluated the efficacy of HSCT for late-infantile patients (6-36 months). In this prospective, longitudinal study, patients were evaluated at a single site according to a standardized protocol. Survival analysis was performed using the Kaplan-Meier method. Differences between groups were estimated using mixed regression models to account for within-person repeated measures. Nineteen late-infantile patients underwent HSCT (March 1997 to January 2020). Compared with untreated patients, transplant recipients had a longer survival probability and improved cognitive and language function. Gross and fine motor development were most affected, with variable results. Asymptomatic patients benefitted the most from transplantation, with normal to near-normal development in all domains and some gross motor delays. Among symptomatic patients, those with disease onset at >12 months of age had better cognitive outcomes than untreated patients. Those with disease onset at ≤12 months were comparable to untreated patients. We found that HSCT prolonged the lifespan and improved the functional abilities of late-infantile patients with Krabbe disease, particularly those who underwent transplantation before onset of symptoms. In addition, our findings support prior literature that reclassifies late-infantile Krabbe disease to be symptom onset at 12 to 36 months of age.
- 1 April 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (13) , 1719-1730
Open AccessLong-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease
Krabbe disease is a rare neurodegenerative disorder caused by a deficiency in galactocerebrosidase. The only effective treatment is hematopoietic stem cell transplantation (HSCT). Approximately 85% of Krabbe disease cases are the infantile subtypes, among which ∼20% are late infantile. Prior studies have demonstrated that HSCT is effective for early-infantile patients (0-6 months of age) who undergo transplantation while asymptomatic, compared with those receiving transplants while symptomatic. However, no studies evaluated the efficacy of HSCT for late-infantile patients (6-36 months). In this prospective, longitudinal study, patients were evaluated at a single site according to a standardized protocol. Survival analysis was performed using the Kaplan-Meier method. Differences between groups were estimated using mixed regression models to account for within-person repeated measures. Nineteen late-infantile patients underwent HSCT (March 1997 to January 2020). Compared with untreated patients, transplant recipients had a longer survival probability and improved cognitive and language function. Gross and fine motor development were most affected, with variable results. Asymptomatic patients benefitted the most from transplantation, with normal to near-normal development in all domains and some gross motor delays. Among symptomatic patients, those with disease onset at >12 months of age had better cognitive outcomes than untreated patients. Those with disease onset at ≤12 months were comparable to untreated patients. We found that HSCT prolonged the lifespan and improved the functional abilities of late-infantile patients with Krabbe disease, particularly those who underwent transplantation before onset of symptoms. In addition, our findings support prior literature that reclassifies late-infantile Krabbe disease to be symptom onset at 12 to 36 months of age.